Tags

Type your tag names separated by a space and hit enter

Congestive heart failure and ventricular arrhythmias in relation to serum magnesium.
Afr J Med Med Sci. 2000 Sep-Dec; 29(3-4):265-8.AJ

Abstract

Congestive Heart Failure (CHF) is associated with biochemical evidence of electrolyte imbalance including magnesium deficit, which may increase myocardial electrical instability, risk of malignant arrhythmias and sudden death. The aim of this study was to determine serum magnesium concentration in 45 patients (Group I; 24 male, 21 female; the average age 49.7 years) with CHF, New York Heart Association (NYHA) Class II, III who were treated with lisinopril [Angiotensin-Converting Enzyme Inhibitor (ACEI)], frusemide (diuretic) and digoxin. All patients were subjected to resting 12-lead electrocardiography (ECG) and ventricular arrhythmias were analysed in relation to serum magnesium concentration at baseline and at end of the fourth week of treatment. Control group (Group II; 24 male, 21 female; the average age 49.3 years) were matched with Group I. Serum magnesium was determined by Atomic Absorption Spectrophotometer (AAS). Statistical analysis was with Student's t-test. It was observed that 6 (13.3%) CHF patients had ventricular arrhythmias at the commencement of the study. This number increased to 17 (37.8%) by the end of the fourth week of treatment. At four weeks, there was significant difference in serum magnesium between CHF patients without arrhythmias (0.69 +/- 0.11 mmol x L(-1)) and those with arrhythmias (0.50 +/- 0.01 mmol x L(-1)), P < 0.0001. Results obtained suggest that CHF patients having hypomagnesemia had higher prevalence of ventricular arrhythmias. It should be stressed, however, that 24 hour ECG monitoring and classification of ventricular arrhythmias according to Lown may give a more accurate picture. Nevertheless, routine serum magnesium assays, as part of the electrolyte profile of CHF patients would assist in early prevention and detection of magnesium depletion. This would go a long way to reduce the susceptibility to lethal arrhythmias and sudden death.

Authors+Show Affiliations

Department of Anatomy, College of Medicine, University of Ibadan, Nigeria.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11714003

Citation

Oladapo, O O., and A O. Falase. "Congestive Heart Failure and Ventricular Arrhythmias in Relation to Serum Magnesium." African Journal of Medicine and Medical Sciences, vol. 29, no. 3-4, 2000, pp. 265-8.
Oladapo OO, Falase AO. Congestive heart failure and ventricular arrhythmias in relation to serum magnesium. Afr J Med Med Sci. 2000;29(3-4):265-8.
Oladapo, O. O., & Falase, A. O. (2000). Congestive heart failure and ventricular arrhythmias in relation to serum magnesium. African Journal of Medicine and Medical Sciences, 29(3-4), 265-8.
Oladapo OO, Falase AO. Congestive Heart Failure and Ventricular Arrhythmias in Relation to Serum Magnesium. Afr J Med Med Sci. 2000 Sep-Dec;29(3-4):265-8. PubMed PMID: 11714003.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Congestive heart failure and ventricular arrhythmias in relation to serum magnesium. AU - Oladapo,O O, AU - Falase,A O, PY - 2001/11/21/pubmed PY - 2002/1/5/medline PY - 2001/11/21/entrez SP - 265 EP - 8 JF - African journal of medicine and medical sciences JO - Afr J Med Med Sci VL - 29 IS - 3-4 N2 - Congestive Heart Failure (CHF) is associated with biochemical evidence of electrolyte imbalance including magnesium deficit, which may increase myocardial electrical instability, risk of malignant arrhythmias and sudden death. The aim of this study was to determine serum magnesium concentration in 45 patients (Group I; 24 male, 21 female; the average age 49.7 years) with CHF, New York Heart Association (NYHA) Class II, III who were treated with lisinopril [Angiotensin-Converting Enzyme Inhibitor (ACEI)], frusemide (diuretic) and digoxin. All patients were subjected to resting 12-lead electrocardiography (ECG) and ventricular arrhythmias were analysed in relation to serum magnesium concentration at baseline and at end of the fourth week of treatment. Control group (Group II; 24 male, 21 female; the average age 49.3 years) were matched with Group I. Serum magnesium was determined by Atomic Absorption Spectrophotometer (AAS). Statistical analysis was with Student's t-test. It was observed that 6 (13.3%) CHF patients had ventricular arrhythmias at the commencement of the study. This number increased to 17 (37.8%) by the end of the fourth week of treatment. At four weeks, there was significant difference in serum magnesium between CHF patients without arrhythmias (0.69 +/- 0.11 mmol x L(-1)) and those with arrhythmias (0.50 +/- 0.01 mmol x L(-1)), P < 0.0001. Results obtained suggest that CHF patients having hypomagnesemia had higher prevalence of ventricular arrhythmias. It should be stressed, however, that 24 hour ECG monitoring and classification of ventricular arrhythmias according to Lown may give a more accurate picture. Nevertheless, routine serum magnesium assays, as part of the electrolyte profile of CHF patients would assist in early prevention and detection of magnesium depletion. This would go a long way to reduce the susceptibility to lethal arrhythmias and sudden death. SN - 0309-3913 UR - https://www.unboundmedicine.com/medline/citation/11714003/Congestive_heart_failure_and_ventricular_arrhythmias_in_relation_to_serum_magnesium_ L2 - https://medlineplus.gov/heartfailure.html DB - PRIME DP - Unbound Medicine ER -